Source-grounded facts extracted from Emergent BioSolutions Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Emergent BioSolutions Inc. reported Q1 2026 results: revenue $156.1, net income $6.8, EPS 0.07.
“($ in millions, except per share amounts) Q1 2026 Q1 2025 % Change Total Revenues $ 156.1 $ 222.2 (30) % Net Income $ 6.8 $ 68.0 (90) % Net Income per Diluted Share $ 0.07 $ 1.19 (94) %”
Emergent BioSolutions Inc. reported First Quarter 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.
“First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23%”
Emergent BioSolutions Inc. reported first quarter ended March 31, 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.
“and is incorporated herein by reference. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS • First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG,”
Emergent BioSolutions Inc. entered into Term Loan Agreement with OrbiMed Royalty & Credit Opportunities V, LP valued at $150 million (effective 2026-04-16).
“On April 16, 2026, Emergent BioSolutions Inc. (the “Company”) entered into a Credit Agreement (the “Term Loan Agreement”) by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent”
Emergent BioSolutions Inc. terminated Prior Credit Agreement with OHA Agency LLC.
“repay all amounts outstanding and terminate commitments under the Credit Agreement dated as of August 30, 2024, by and among the Company, the lenders from time to time party thereto and OHA Agency LLC as administrative agent (as amended, the "Prior Credit Agreement")”
Emergent BioSolutions Inc. incurred term loan of $150 million with OrbiMed Royalty & Credit Opportunities V, LP at Term SOFR (subject to a floor of 3.00%) plus 6.25% per annum maturing April 16, 2031.
“The Term Loan Agreement provides for (i) a term loan (the “Initial Term Loan”) in an aggregate principal amount equal to $150 million, which was drawn in full on the date of entry into the Term Loan Agreement (the “Closing Date”)”
Jennifer Fox departed as Executive Vice President External Affairs, General Counsel and Corporate Secretary at Emergent BioSolutions Inc..
“Emergent BioSolutions, Inc. (the “Company”) announced that Jennifer Fox is resigning as Executive Vice President External Affairs, General Counsel and Corporate Secretary of the Company to pursue an opportunity outside of the Company and will continue in her current role until August 16, 2024.”
Emergent BioSolutions Inc. amended credit facility of reduce available commitments under the Revolving Credit Facility to $270.0 million through July 30, 2024, to $225.0 mill with Wells Fargo Bank, National Association at amend the interest rate benchmark in the definition of Applicable Margin from (i.
“The Seventh Amendment amends the Existing Credit Agreement to, among other things, (a) reduce available commitments under the Revolving Credit Facility to $270.0 million through July 30, 2024, to $225.0 million from July 31, 2024 through October 30, 2024, and to $200.0 million on October 31, 2024 and thereafter; (b) amend the interest rate benchmark in the definition of Applicable Margin from (i) 5.00% per annum to 7.00% per annum with respect to Base Rate Loans and (ii) 6.50% per annum to 8.50% per annum with respect to SOFR Loans, RFR Loans and Eurocurrency Rate Loans;”
Emergent BioSolutions Inc. amended Seventh Amendment with Wells Fargo Bank, National Association valued at $270.0 million (effective 2024-04-29).
“On April 29, 2024, Emergent BioSolutions Inc. (the “Company”) entered into a Consent, Waiver and Seventh Amendment to the Amended and Restated Credit Agreement (the “Seventh Amendment”) (the “Seventh Amendment”), among the Company, as borrower, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”) and certain lenders party thereto.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.